Wall Street analysts ranked Recursion Pharmaceuticals Inc. (RXRX) the top AI stock on April 12, 2026, per Yahoo Finance. Shares closed at $14.50 USD, down 1.2%.
Twelve of 15 analysts rate RXRX Buy, according to Yahoo Finance consensus. Average price target stands at $28.40 USD, implying 96% upside from the April 12 close.
Broader Market Snapshot
CNN Fear & Greed Index hit 16, signaling extreme fear, on April 12, 2026, per CNN Business. Bitcoin fell 2.7% to $71,380 USD, per CoinMarketCap. Ether dropped 3.8% to $2,213.40 USD.
Nvidia Corp. (NVDA) shares gained 0.8% to $145.20 USD, per Nasdaq. RXRX market cap reached $4.2 billion USD with 2.1 million shares traded, per Yahoo Finance.
Recursion's AI Platform
Recursion built the Recursion Operating System, which applies machine learning to cellular images for drug candidate identification, per company filings.
Recursion deployed BioHive-2 supercomputer in 2025, equipped with 500 Nvidia H100 GPUs. This doubled phenotypic screening capacity, Recursion stated in its 2025 annual report.
Recursion launched Phenom-2 model on April 10, 2026. The model achieves 92% accuracy in protein interaction predictions, per Recursion press release. Bayer AG licensed it for oncology programs.
CEO Chris Gibson stated in Q1 earnings call, "Our AI decodes biology at scale." Recursion maintains 450 petabytes of proprietary data for training, per the same call.
Q1 2026 Earnings Highlights
Recursion posted Q1 2026 revenue of $18.5 million USD, up 45% year-over-year, in its April 2026 earnings release. Net loss shrank to $120 million USD from $145 million USD.
Cash stood at $450 million USD. JPMorgan analyst Eric Joseph upgraded to Overweight with $30 USD target, citing 15 AI-discovered pipeline candidates.
Piper Sandler analyst Christopher Raymond kept Buy rating. He projects $250 million USD 2027 revenue from Nvidia collaboration, per April 12 note.
Enterprise value to sales multiple hit 12.5, below AI peers' 25 average, per Yahoo Finance data.
Analyst Views and Ownership
Fifteen analysts deliver 80% Buy ratings. Median target: $27.00 USD. Truist Securities' Swayampula Ramakanth started Buy coverage with $40 USD target.
Ramakanth called RXRX a "hidden gem in AI biotech" and forecast 200% higher clinical trial success rates, per his April 12 initiation note.
Retail investors hold 12%, per Nasdaq. Vanguard Group owns 8%. ARK Invest bought 1 million shares in Q1 2026, per 13F filings.
Short interest dropped to 15% from 22% in March, per Ortex. Options volume surged 30%, per CBOE data.
AI Drug Discovery Market
Global AI drug discovery market hit $5 billion USD in 2026, per Grand View Research. Sector grows at 30% CAGR to 2030. Recursion claims 5% share.
Recursion mapped 30 trillion cellular relationships, per Q1 call. U.S. FDA greenlit two candidates for Phase 2 on April 8, 2026, per Recursion. REC-994 earned fast-track for neurology.
Risks and Macro Factors
Recursion reports 25% pipeline success rate, topping industry 10% average, per internal data. Q1 cash burn: $90 million USD. Runway lasts to 2028, debt-free.
Federal Reserve held rates at 4.75% on April 12, 2026. Q1 GDP grew 2.1%, per Bureau of Economic Analysis. Goldman Sachs' Paul Choi rated Hold at $18 USD target over valuation.
Sector Performance and Trends
Healthcare AI gained 45% year-to-date versus S&P 500's 8%, per Yahoo Finance. AI biotech venture funding totaled $12 billion USD in Q1 2026, per PitchBook.
Wedbush's Dan Ives dubbed RXRX the "next big AI winner," predicting 5x growth by 2030, per April 12 client note.
ARK Genomic Revolution ETF includes RXRX. ETF saw $500 million USD inflows that week, per ETF.com.
Forward Outlook
Q2 earnings arrive May 15, 2026. Consensus calls $22 million USD revenue, -$0.35 USD EPS, per Yahoo Finance. 30-day implied volatility: 65%. Beta to Nasdaq: 1.8.
RXRX offers pure-play AI stock exposure in biotech amid volatility.
